peter-hamar
Peter Hamar, MD, PhD, Dsc, med. Habil.
Associate Professor of Medicine

Education

DEGREE DEPARTMENT UNIVERSITY YEAR
postdoctoral fellow Researcher exchange program University Clinic Heidelberg, Germany 2002- 2003
Ph.D Nephrology Semmelweis University 1994-1999
Medical Student   Semmelweis University 1989-1994
Premedical Student   Rutgers University 1987–1988

Biography

Dr. Peter Hamar is an Associate professor at Semmelweis University, Faculty of General Medicine, Institute of Pathophysiology and published. Peter Hamar, MD, PhD, is associate professor at Semmelweis University. His scientific interest is to understand the pathophysiologic role of small RNAs in vivo with rodent models. A major roadblock to harnessing small RNSs for therapy is delivery to targeted cells and intracellular compartment. We thus, study delivery methods. Besides being a PI at Semmelweis, P. Hamar intensely collaborates with the Immune Disease Institute at Harvard Medical School, Boston, USA. We were first to harness RNA-interference for the kidney. Recently we demonstrated endosomal escape of siRNA from lipid nanoparticles with high resolution microscopy (Nat Genet). P. Hamar has co-authored.

 

Research Interest

  • Immunologic aspects
  • Post-transcriptional gene-expression regulation in renal diseases and atherosclerosis.

Scientific activities

Employment History
2017 Apr. - present scientific Advisor, Clinical Experimental Research Institute, Semmelweis University, Budapest, Hungary
2017 March. - present scientific advisor, principal investigator. Translational Medicine Institute, Pécs University, Pécs, Hungary
1994-2017 assistant-, associate- professor. Institute of Pathophysiology, Semmelweis University, Budapest, Hungary
2017 May-July visiting professor, Sun-Yat sen Hospital, Guangzhou, China
2014 Marc-August visiting professor, Immune Dis Institute, Harvard Medical School, Boston, MA USA (Prof Judy Liebermann)
2006–2009 Scientific Advisor, Semmelweis University, Budapest, Hungary
2004-2005 Principal Investigator, Sun-Yat sen Uni, Guangzhou, China
2003 (July-August) Invited postdoctoral fellow, CBR Research Institute, Harvard Medical School, Boston, MA USA
HONORS AND AWARDS
International
  • 2001 - Young investigator award, by: International Nephrological Society (ISN)
  • 1997 - Best abstract by young investigator, by: European Dialysis and Transplant Association (EDTA)
  • 1997 - Best poster by young investigator, by: European Society of Organ Transplantation (ESOT)

Hungarian

  • 2012-14 and 2016-18 - Semmelweis University – Merit scholarship for excellence in research and teaching
  • 2010 - Semmelweis University – Distinction for excellence in research
  • 2010 - Sanofi-Aventis/Chinoin Hungarian Research Price: The role of the immune system in the development of chronic renal failure
  • 2009, 2002 - Gedeon Richter research award, by: Gedeon Richter Co
  • 2009, 2001, 1999 - Outstanding achievement, by: Bolyai Grant Committee
  • 2005, 2003, 2000 - Young investigator award, by: Hungarian Physiological Society
  • 2005 - Best international publication, by: Hungarian Nephrological Society
  • 2002 - László Hársing award, by: Hungarian Kidney Foundation
  • 2002 - Antal Babics award, by: Semmelweis University
  • 1997 - Best congress presentation: first place, by: Hungarian Nephrological Society
  • 1993 - First place, by: Semmelweis University, Scientific Congress of Students

Committee Memberships

  • 2015 – European Commission, Horizon 2020 – 2 grant evaluation committees
  • 2012,14 – Korányi Scientific Committee (head of the evaluator committee)
  • 2011 – Tempus application evaluator
  • 2010 – National Science and Technology Office (NKTH) (evaluator)
  • 2009 – EURECAM: European Renal and Cardiology Working Group member
  • 2007 – Hungarian Research Fund (OTKA) (evaluator, KISOR committee member)
  • 2007 – Welcome Trust research grants (evaluator)
  • 2006 – Students Scientific Congress of Semmelweis University (evaluator)
  • 2006 Scientific Grants submitted to the Croatian Ministry of Sciences (evaluator)
  • 2004 – Gerson Lehrmann Consulting Group (New York, NY, USA) (consultant)
  • 2003 – Novartis: Allergy and Inflammation contest (evaluator)
  • 1999 – Korányi Scientific Committee (evaluator)

Scientific Society Memberships

  • 2015 – Hungarian Laboratory Diagnostics Society (MLDT) (member)
  • 2014 – European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
  • 2006 - Hungarian Physiologic Society (MÉT) (member of the executive committee)
  • 2003-09 Hungarian Immunological Society (MIT) (member)
  • 2002-09 International Society of Nephrology (ISN) (member)
  • 2000 - European Kidney Research Association (EKRA) (founding member)
  • 1998 - Hungarian Physiological Society (MÉT) (member)
  • 1996 - Hungarian Nephrological Society (MNT-MANET) (member)

Publications

  1. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J: Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. PROC NAT ACAD SCI (USA) (2004) IF: 10.452, citations: 207
  2. Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, Manoharan M, Kirchhausen T, Lieberman J: Cytosolic release of endocytosed lipid-formulated siRNAs occurs from maturing endosomes during a narrow time window, triggering galectin-mediated autophagy. Nat Biotec (2015). IF: 41.514, citations: 50
  3. Le MTN, Hamar P, Guo CY, Basar E, Perdigao-Henriques R, Balaj L, Lieberman J: miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J CLIN INVEST (2014). IF: 13.765, citations: 94
  4. Gilboa-Geffen A, Hamar P, Le MT, Wheeler LA, Trifonova R, Petrocca F, Wittrup A, Lieberman J: Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. Mol Cancer Ther (2015). IF: 5.33, citations: 10
  5. Racz Z, Godo M, Revesz C, Hamar P: Immune activation and target organ damage are consequences of hydrodynamic treatment but not delivery of naked siRNAs in mice. NUCL AC THER (2011). IF: 2.797, citations: 12
  6. Kiss N, Hamar P: Histopathologic Evaluation of Contrast Induced Acute Kidney Injury (CI-AKI) Rodent Models. Biomed Res Int (2016). IF: 2.476
  7. Hamar P, Kerjaschki D: Blood capillary rarefaction and lymphatic capillary neoangiogenesis are key contributors to renal allograft fibrosis in an ACE inhibition rat model. AM J PHYSIOL-HEART (2016). IF: 3.85
  8. Buday A, Orsy P, Godo M, Mozes M, Kokeny G, Lacza Z, Koller A, Ungvari Z, Gross ML, Benyo Z, Hamar P: Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production. AM J PHYSIOL-HEART (2010). IF: 3.881, citations: 37
  9. Kaucsar T, Revesz C, Godo M, Krenacs T, Albert M, Szalay C, Rosivall L, Benyo Z, Batkai S, Thum T, Szénási G, Hamar P: Activation of the miR-17 Family and miR-21 During Murine Kidney Ischemia-Reperfusion Injury. NUCL AC THER (2013). IF: 2.888, citations: 19
  10. Nemeth Z, Kokeny G, Godo M, Mozes M, Rosivall L, Gross ML, Ritz E, Hamar P: Increased renoprotection with ACE inhibitor plus aldosterone antagonists compared to monotherapies. NEPHROL DIAL TRANSPLANT (2009). IF: 3.306, citations: 16
  11. Kaucsar T, Racz Z, Hamar P: Post-transcriptional gene-expression regulation by micro RNA network in renal disease. ADV DRUG DELIV REV (2010). IF: 13.577, citations: 15
  12. Szalay CI, Erdelyi K, Kokeny G, Lajtar E, Godó M, Revesz C, Kaucsár T, Kiss N, Sarkozy M, Csont T, Krenács T, Szénási G, Pacher P, Hamar P: Oxidative/Nitrative Stress and Inflammation Drive Progression of Doxorubicin-Induced Renal Fibrosis in Rats as Revealed by Comparing a Normal and a Fibrosis-Resistant Rat Strain. PLoS One (2015). IF: 3.54, citations: 8
  13. Rácz Z, Hamar P: RNA interference in research and therapy of renal diseases. Contrib Nephrol (2008). IF: 1.94, citations: 7
  14. Kaucsár T, Godó M, Révész C, Kovács M, Mócsai A, Kiss N, Albert M, Krenács T, Szénási G, Hamar P: Urine/Plasma Neutrophil Gelatinase Associated Lipocalin Ratio Is a Sensitive and Specific Marker of Subclinical Acute Kidney Injury in Mice. PLoS One (2016). IF: 3.54, citations: 1
  15. Kokeny G, Nemeth Z, Godo M, Hamar P: The Rowett rat strain is resistant to renal fibrosis. NEPHROL DIAL TRANSPLANT (2010). IF: 3.564, citations: 1
  16. Hamar P, Muller V, Kohnle M, Witzke O, Albrecht K H, Philipp T, Heemann U: Metabolic factors have a major impact on kidney allograft survival. TRANSPLANTATION (1997). IF: 3.441, citations: 31
  17. Hamar P, Liu S, Viklicky O, Szabo A, Muller V, Heemann U: Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. TRANSPLANTATION (2000). IF: 4.035, citations: 6
  18. Su F, Hu X, Jia W, Gong C, Song E, Hamar P: Glutathione S transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res (2003). IF: 2.12, citations: 54
  19. Yao H, Song E, Chen J, Hamar P: Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br J Cancer (2004). IF: 2.87, citations: 41
  20. Heemann U, Szabo A, Hamar P, Müller V, Witzke O, Lutz J, Philipp T: Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury : possible connection to an interleukin-6-dependent pathway. Am J Pathol (2000). IF: 5.64, citations: 107
  21. Losonczy G, Kriston T, Szabó A, Müller V, Harvey J, Hamar P, Heemann U, Baylis C: Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res (2000) IF: 3.783, citations: 39
  22. Kaucsár T, Bodor C, Godó M, Szalay C, Révész C, Németh Z, Mózes M, Szénási G, Rosivall L, Sőti C, Hamar P: LPS-induced delayed preconditioning is mediated by Hsp90 and involves the heat shock response in mouse kidney. PLoS One (2014) IF: 4.17, citations: 4

Autoimmune Journal Flyer